COLLPLANT BIOTECHNOLOGIES LT (CLGNXXXX)
Institutional ownership reported to the SEC as of Q2 2026, across 29 quarters.
1
Reporting holders
$25
Reported value
0.0%
Held as options
+0
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| Parallel Advisors, LLC | $25 | 71 | 0.00% | 23q | HELD |
Five percent filings
Anyone crossing 5% of a company must say so within days - far sooner than the next quarterly holdings report. A 13D declares an intent to influence the company; a 13G is the passive version. See all activist filings →
| Filed | Form | Filer | % of class |
|---|---|---|---|
| 2026-08-21 | 13D/A | The Loewenbaum 1992 Trustwith 6 co-filers | 17.5% |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | $25 | 71 | 0 | 0 | 0 | 0.0% |
| Q1 2026 | 1 | $38 | 71 | 0 | 0 | 1 | 0.0% |
| Q4 2025 | 1 | $4.6K | 3,253 | 0 | 0 | 0 | 0.0% |
| Q3 2025 | 1 | $8.8K | 3,253 | 0 | 0 | 0 | 0.0% |
| Q2 2025 | 1 | $4.4K | 3,254 | 0 | 0 | 0 | 0.0% |
| Q1 2025 | 1 | $8.4K | 3,254 | 0 | 0 | 0 | 0.0% |
| Q4 2024 | 1 | $11.7K | 3,253 | 0 | 0 | 0 | 0.0% |
| Q3 2024 | 1 | $16.2K | 3,253 | 0 | 0 | 0 | 0.0% |
| Q2 2024 | 1 | $16.2K | 3,254 | 0 | 0 | 1 | 0.0% |
| Q1 2024 | 1 | $21.8K | 4,078 | 0 | 1 | 0 | 0.0% |
| Q4 2023 | 1 | $454 | 71 | 0 | 0 | 1 | 0.0% |
| Q3 2023 | 1 | $47.7K | 8,556 | 0 | 0 | 1 | 0.0% |
| Q2 2023 | 1 | $78.5K | 9,614 | 0 | 0 | 0 | 0.0% |
| Q1 2023 | 1 | $67.5K | 9,614 | 0 | 0 | 1 | 0.0% |
| Q4 2022 | 1 | $105.5K | 12,639 | 0 | 0 | 1 | 0.0% |
| Q3 2022 | 1 | $111.0K | 16,382 | 0 | 0 | 0 | 0.0% |
| Q2 2022 | 1 | $131.0K | 16,382 | 0 | 0 | 0 | 0.0% |
| Q1 2022 | 1 | $192.0K | 16,382 | 0 | 0 | 1 | 0.0% |
| Q4 2021 | 1 | $328.0K | 20,066 | 0 | 0 | 1 | 0.0% |
| Q3 2021 | 1 | $360.0K | 21,294 | 0 | 1 | 0 | 0.0% |
| Q2 2021 | 2 | $11.7M | 552,029 | 0 | 0 | 1 | 0.0% |
| Q1 2021 | 15 | $24.4M | 1,813,871 | 10 | 4 | 0 | 0.0% |
| Q4 2020 | 6 | $10.2M | 950,357 | 2 | 3 | 0 | 0.0% |
| Q3 2020 | 7 | $7.4M | 890,518 | 1 | 4 | 1 | 0.0% |
| Q2 2020 | 6 | $6.3M | 628,916 | 4 | 1 | 0 | 0.0% |
| Q1 2020 | 3 | $1.5M | 162,398 | 3 | 0 | 0 | 0.0% |
| Q4 2019 | 1 | $1.0K | 106 | 1 | 0 | 0 | 0.0% |
| Q3 2019 | 1 | $21.0K | 5,304 | 0 | 1 | 0 | 0.0% |
| Q2 2019 | 2 | $52.0K | 12,902 | 2 | 0 | 0 | 0.0% |